Rotigotine

Known as: (6S)-6-(propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol, (+--)-5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol, rotigotine, (+--)- 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
BACKGROUND Non-motor symptoms of Parkinson's disease (PD) represent major causes of morbidity. RECOVER, a randomized controlled… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
In a multinational, double-blind, placebo-controlled trial (NCT00474058), 287 subjects with Parkinson's disease (PD) and… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2010
2010
This randomized, double-blinded, placebo-controlled trial (NCT00135993) assessed efficacy and safety of the dopamine agonist… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Continuous administration of a dopamine agonist could be used to treat patients with restless legs syndrome. Our aim… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2008
2008
Rotigotine (Neupro®) is a non-ergoline dopamine agonist developed for the once daily treatment of Parkinson’s disease (PD) using… (More)
  • table 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND In patients experiencing motor fluctuations, a major treatment challenge is the reduction of "off" time, particularly… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Continuous dopaminergic drug delivery is an unmet medical need in advanced Parkinson's disease. The aim of this trial… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Rotigotine is a new, non-ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
OBJECTIVE To assess the response to the rotigotine transdermal system (Neupro; Schwarz Pharma Ltd, Monheim, Germany), a… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Review
2005
Review
2005
Rotigotine is a nonergolinic dopamine D3/D2/D1 receptor agonist delivered via a transdermal system and has been evaluated for the… (More)
Is this relevant?